Rafael Caparica

948 total citations
35 papers, 579 citations indexed

About

Rafael Caparica is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Rafael Caparica has authored 35 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Rafael Caparica's work include Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Cancer Treatment Studies (8 papers). Rafael Caparica is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Cancer Treatment Studies (8 papers). Rafael Caparica collaborates with scholars based in Belgium, Italy and Brazil. Rafael Caparica's co-authors include Evandro de Azambuja, Matteo Lambertini, Mariana Brandão, Martine Piccart, Daniel Eiger, Marco Bruzzone, Marcello Ceppi, Claudia De Angelis, Noam Pondé and Gilberto de Castro and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Rafael Caparica

34 papers receiving 575 citations

Peers

Rafael Caparica

ONCOL

PRM

SURGE

Thiago Vidotto United States

Johnique T. Atkins United States

Zhenbin Shen China

Jinchun Yan United States

Yueyao Du China

Cynthia G. Healy United States

Daniela Morales-Espinosa Spain

Osamu Nagakawa Japan

Yangzi Tian China

Thiago Vidotto United States

Rafael Caparica

302 ×0.9

ONCOL

313 ×1.2

PRM

173 ×1.0

294 ×1.8

74 ×1.1

SURGE

Citations per year, relative to Rafael Caparica Rafael Caparica (= 1×) peers Thiago Vidotto

Countries citing papers authored by Rafael Caparica

Since Specialization

Citations

This map shows the geographic impact of Rafael Caparica's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafael Caparica with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafael Caparica more than expected).

Fields of papers citing papers by Rafael Caparica

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafael Caparica. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafael Caparica. The network helps show where Rafael Caparica may publish in the future.

Co-authorship network of co-authors of Rafael Caparica

This figure shows the co-authorship network connecting the top 25 collaborators of Rafael Caparica. A scholar is included among the top collaborators of Rafael Caparica based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafael Caparica. Rafael Caparica is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Solomon, Benjamin, Daniel S.W. Tan, Gilberto de Castro, et al.. (2025). The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer Research Communications. 5(4). 632–646. 1 indexed citations

Lindsay, Colin R., Rajwanth Veluswamy, Gilberto de Castro, et al.. (2023). A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation. International Journal of Radiation Oncology*Biology*Physics. 118(1). e13–e14. 1 indexed citations

Marta, Guilherme Nader, Véronique Debien, Daniel Eiger, et al.. (2022). Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. 127(10). 1799–1807. 1 indexed citations

Harada, Guilherme, Renata Colombo Bonadio, Rafael Caparica, et al.. (2021). Effectiveness and toxicity of adjuvant chemotherapy in patients with non-small cell lung cancer. Jornal Brasileiro de Pneumologia. 47(3). e20200378–e20200378. 8 indexed citations

Chanzá, Nieves Martínez, Philippe Barthélémy, Thierry Gil, et al.. (2021). Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial). BMC Cancer. 21(1). 1292–1292. 12 indexed citations

Caparica, Rafael, Marco Bruzzone, Elisa Agostinetto, et al.. (2021). Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. ESMO Open. 6(2). 100066–100066. 34 indexed citations

Agostinetto, Elisa, Rafael Caparica, Marco Bruzzone, et al.. (2021). CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis. ESMO Open. 6(2). 100091–100091. 15 indexed citations

Caparica, Rafael, Claudia De Angelis, François Richard, et al.. (2021). Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. Clinical Breast Cancer. 22(4). 308–318. 4 indexed citations

Caparica, Rafael, François Richard, Mariana Brandão, et al.. (2020). Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. Clinical Breast Cancer. 20(3). 262–273.e7. 16 indexed citations

10.

Caparica, Rafael, Alain Hendlisz, Evandro de Azambuja, et al.. (2020). Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy. BMJ Supportive & Palliative Care. 14(e2). e1882–e1888. 3 indexed citations

11.

Franzoi, Maria Alice, Caroline Vandeputte, Daniel Eiger, et al.. (2020). Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. Breast Cancer Research and Treatment. 181(1). 199–209. 27 indexed citations

12.

Caparica, Rafael, Marco Bruzzone, Marcello Ceppi, et al.. (2020). Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology. 149. 102940–102940. 5 indexed citations

13.

Agostinetto, Elisa, Rafael Caparica, & Evandro de Azambuja. (2020). CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?. ESMO Open. 5(6). e001132–e001132. 5 indexed citations

14.

Caparica, Rafael, Mariana Brandão, & Martine Piccart. (2019). Systemic treatment of patients with early breast cancer: recent updates and state of the art. The Breast. 48. S7–S20. 18 indexed citations

15.

Brandão, Mariana, Rafael Caparica, Daniel Eiger, & Evandro de Azambuja. (2019). Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Annals of Oncology. 30(Suppl_10). x27–x42. 61 indexed citations

16.

Caparica, Rafael, et al.. (2019). FOLFIRI as second-line treatment of metastatic biliary tract cancer patients. SHILAP Revista de lepidopterología. 9(2). e2019087–e2019087. 15 indexed citations

17.

Caparica, Rafael, Marco Bruzzone, Francesca Poggio, et al.. (2018). Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment. 174(1). 27–37. 34 indexed citations

18.

Caparica, Rafael, Cheng Tzu Yen, Renata A. Coudry, et al.. (2016). Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations. Journal of Thoracic Oncology. 12(1). 141–144. 49 indexed citations

19.

Caparica, Rafael, Gilberto de Castro, Ignacio Gil‐Bazo, et al.. (2016). BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. Critical Reviews in Oncology/Hematology. 101. 32–39. 14 indexed citations

20.

Passiglia, Francesco, Rafael Caparica, Elisa Giovannetti, et al.. (2016). The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Expert Opinion on Investigational Drugs. 25(4). 385–392. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact